NTLA-2001
Phase 1Completed 0 watching 0 views this week💤 Quiet
28
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy
Conditions
Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy, Transthyretin-Related (ATTR) Familial Amyloid Cardiomyopathy, Wild-Type Transthyretin Cardiac Amyloidosis
Trial Timeline
Nov 5, 2020 → Sep 12, 2025
NCT ID
NCT04601051About NTLA-2001
NTLA-2001 is a phase 1 stage product being developed by Intellia Therapeutics for Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy. The current trial status is completed. This product is registered under clinical trial identifier NCT04601051. Target conditions include Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy, Transthyretin-Related (ATTR) Familial Amyloid Cardiomyopathy, Wild-Type Transthyretin Cardiac Amyloidosis.
Hype Score Breakdown
Clinical
10
Activity
5
Company
5
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04601051 | Phase 1 | Completed |